Structure Therapeutics up after weight-loss drug succeeds mid-stage trial

Structure Therapeutics

08/12/2025 13:49

Updates

** Shares of Structure Therapeutics GPCR.O rise 15.7% to $41.3 premarket

** GPCR's experimental drug aleniglipron at a dosage of 120mg showed an 11.3% reduction in weight in a mid-stage study, a figure that was statistically significant compared to placebo at 36 weeks

 ** The company plans to initiate a late-stage trial in mid-2026

 ** Another study exploring higher doses of aleniglipron showed weight loss of up to 15.3% at 36 weeks

** The current landscape for obesity treatments includes Danish drugmaker Novo Nordisk's NOVOb.CO Wegovy and Eli Lilly's LLY.N Zepbound, both of which dominate the market

** Viking Therapeutics' experimental weight-loss pill VK2735 previously failed to surpass Wall Street expectations in August

** As of last close, GPCR stock was up 27.4% YTD

(Reporting by Padmanabhan Ananthan)

((Padmanabhan.Ananthan@thomsonreuters.com))